Role of inflammation in drug-induced liver injury

Drug-Induced Liver Disease

Volumn , Issue , 2013, Pages 157-173

  Roth, Robert A ^a   Ganey, Patricia E ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Acetaminophen; Coagulation system; Halothane; Idiosyncratic hepatotoxicity; Inflammation; Interferon gamma; Kupffer cells; Lipopolysaccharide; Natural killer cells; Neutrophils; Nonsteroidal antiinflammatory drugs; Trovafloxacin

Indexed keywords

EID: 84882639465     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-387817-5.00010-8     Document Type: Chapter

References (138)

1. Hansen J.D., Vojtech L.N., Laing K.J. Sensing disease and danger: a survey of vertebrate PRRs and their origins. Dev Comp Immunol 2011, 35(9):886-897.
2. Wu M.H., Zang P., Huang X. Toll-like receptors in innate immunity and infectious diseases. Front Med in China 2010, 4(4):385-393.
3. Xiang M., Fan J. Pattern recognition receptor-dependent mechanisms of acute lung injury. Mol Med 2010, 16(1-2):69-82.
4. Eleftheriadis T., Lawson B.R. Toll-like receptors and kidney diseases. Inflamm Allergy-Drug Targets 2009, 8(3):191-201.
5. Senior J.R. What is idiosyncratic hepatotoxicity? What is it not?. J Hepatol 2008, 47(6):1813-1815.
6. Roth R.A., Ganey P.E. Intrinsic versus idiosyncratic drug-induced hepatotoxicity-two villains or one?. J Pharmacol Exp Ther 2010, 332(3):692-697.
7. Larson A.M., Polson J., Fontana R.J., Davern T.J., Lalani E., Hynan L.S., et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. J Hepatol 2005, 42(6):1364-1372.
8. Lee W.M. Acetaminophen and the U.S. Acute Liver Failure Study Group: lowering the risks of hepatic failure. J Hepatol 2004, 40(1):6-9.
9. Jaeschke H., McGill M.R., Williams C.D., Ramachandran A. Current issues with acetaminophen hepatotoxicity-a clinically relevant model to test the efficacy of natural products. Life Sci 2011, 88(17-18):737-745.
10. Kaplowitz N. Acetaminophen hepatotoxicity: what do we know, what don't we know, and what do we do next?. J Hepatol 2004, 40(1):23-26.
11. Martin-Murphy B.V., Holt M.P., Ju C. The role of damage associated molecular pattern molecules in acetaminophen induced liver injury in mice. Toxicol Lett 2010, 192(3):387-394.
12. Imaeda A.B., Watanabe A., Sohail M.A., Mahmood S., Mohamadnejad M., Sutterwala F.S., et al. Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome. J Clin Invest 2009, 119(2):305-314.
13. Yohe H.C., O'Hara K.A., Hunt J.A., Kitzmiller T.J., Wood S.G., Bement J.L., et al. Involvement of toll-like receptor 4 in acetaminophen hepatotoxicity. Am J Physiol-Gastrointest Liver Physiol 2006, 290(6):1269-1279.
14. Xu J., Zhang X., Monestier M., Esmon N.L., Esmon C.T. Extracellular histones are mediators of death through TLR2 and TLR4 in mouse fatal liver injury. J Immunol 2011, 187(5):2626-2631.
15. Chen G.Y., Tang J., Zheng P., Liu Y. CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science 2009, 323(5922):1722-1725.
16. Dear J.W., Simpson K.J., Nicolai M.P., Catterson J.H., Street J., Huizinga T., et al. Cyclophilin A is a damage-associated molecular pattern molecule that mediates acetaminophen-induced liver injury. J Immunol 2011, 187(6):3347-3352.
17. Raiford D.S., Thigpen M.C. Kupffer cell stimulation with Cornybacterium parvum reduces some cytochrome P450-dependent activities and diminishes acetaminophen and carbon tetrachloride-induced liver injury in the rat. Toxicol Appl Pharmacol 1994, 129(1):36-45.
18. Campion S.N., Johnson R., Aleksunes L.M., Goedken M.J., van Rooijen N., Scheffer G.L., et al. Hepatic Mrp4 induction following acetaminophen exposure is dependent on Kupffer cell function. Am J Physiol-Gastrointest Liver Physiol 2008, 295(2):294-304.
19. Laskin D., Pilaro A.M. Potential role of activated macrophages in acetaminophen hepatotoxicity. I. Isolation and characterization of activated macrophages from rat liver. Toxicol Appl Pharmacol 1986, 86(2):204-215.
20. Laskin D.L., Pilaro A.M., Ji S. Potential role of activated macrophages in acetaminophen hepatotoxicity. II. Mechanism of macrophage accumulation and activation. Toxicol Appl Pharmacol 1986, 86(2):216-226.
21. Trepicchio W.L., Bozza M., Bouchard P., Dorner A.J. Protective effect of rhlL-11 in murine model of acetaminophen-induced hepatotoxicity. Toxicol Pathol 2001, 29(2):242-249.
22. Laskin D.L., Gardner C.R., Price V.F., Jollow D.J. Modulation of macrophage functioning abrogates the acute hepatotoxicity of acetaminophen. J Hepatol 1995, 21(4):1045-1050.
23. Michael S.L., Pumford N.R., Mayeux P.R., Niesman M.R., Hinson J.A. Pretreatment of mice with macrophage inactivators decreases acetaminophen hepatotoxicity and the formation of reactive oxygen and nitrogen species. J Hepatol 1999, 30(1):186-195.
24. Goldin R.D., Ratnayaka I.D., Breach C.S., Brown I.N., Wickramasinghe S.N. Role of macrophages in acetaminophen (paracetamol)-induced hepatotoxicity. J Pathol 1996, 179(4):432-435.
25. Ju C., Reilly T.P., Bourdi M., Radonovich M.F., Brady J.N., George J.W., et al. Protective role of Kupffer cells in acetaminophen-induced hepatic injury in mice. Chem Res Toxicol 2002, 15(12):1504-1513.
26. Holt M.P., Yin H., Ju C. Exacerbation of acetaminophen-induced disturbances of liver sinusoidal endothelial cells in the absence of Kupffer cells in mice. Toxicol Lett 2010, 194(1-2):34-41.
27. Ito Y., Abril E.R., Bethea N.W., McCuskey R.S. Role of nitric oxide in hepatic microvascular injury elicited by acetaminophen in mice. Am J Physiol-Gastrointest Liver Physiol 2004, 286(1):60-67.
28. Holt M.P., Cheng L., Ju C. Identification and characterization of infiltrating macrophages in acetaminophen-induced liver injury. J Leukoc Biol 2008, 84(6):1410-1421.
29. Dambach D.M., Watson L.M., Gray K.R., Durham S.K., Laskin D.L. Role of CCR2 in macrophage migration into the liver during acetaminophen-induced hepatotoxicity in the mouse. J Hepatol 2002, 35(5):1093-1103.
30. Hogaboam C.M., Bone-Larson C.L., Steinhauser M.L., Lukacs N.W., Colletti L.M., Simpson K.J., et al. Novel CXCR2-dependent liver regenerative qualities of ELR-containing CXC chemokines. J Fed Am Societies Exp Biol 1999, 13(12):1565-1574.
31. Matsumaru K., Ji C., Kaplowitz N. Mechanisms for sensitization to TNF-induced apoptosis by acute glutathione depletion in murine hapatocytes. J Hepatol 2003, 37(6):1425-1434.
32. Dambach D.M., Durham S.K., Laskin J.D., Laskin D.L. Distinct roles of NF-kappaB p50 in the regulation of acetaminophen-induced inflammatory mediator production and hepatotoxicity. Toxicol Appl Pharmacol 2006, 211(2):157-165.
33. Blazka M.E., Wilmer J.L., Holladay S.D., Wilson R.E., Luster M.I Role of proinflammatory cytokines in acetaminophen hepatotoxicity. Toxicol Appl Pharmacol 1995, 133(1):43-52.
34. Blazka M.E., Elwell M.R., Holladay S.D., Wilson R.E., Luster M.I. Histopathology of acetaminophen-induced liver changes: role of interleukin 1 alpha and tumor necrosis factor alpha. Toxicol Pathol 1996, 24(2):181-189.
35. Ishida Y., Kondo T., Tsuneyama K., Lu P., Takayasu T., Mukaida N. The pathogenic roles of tumor necrosis factor receptor p55 in acetaminophen-induced liver injury in mice. J Leukoc Biol 2004, 75(1):59-67.
36. Simpson K.J., Lukacs N.W., McGregor A.H., Harrsion D.J., Streiter R.M., Kunkel S.L. Inhibition of tumor necrosis factor alpha does not prevent experimental paracetamol-induced hepatic necrosis. J Pathol 2000, 190(4):489-494.
37. Boess F., Bopst M., Althaus R., Polsky S., Cohen S.D., Eugster H.P., et al. Acetaminophen hepatotoxicity in tumor necrosis factor/lymphotoxin-alpha gene knockout mice. J Hepatol 1998, 27(4):1021-1029.
38. Gardner C.R., Laskin J.D., Dambach D.M., Chiu H., Durham S.K., Zhou P., et al. Exaggerated hepatotoxicity of acetaminophen in mice lacking tumor necrosis factor receptor-1. Potential role of inflammatory mediators. Toxicol Appl Pharmacol 2003, 192(2):119-130.
39. James L.P., Kurten R.C., Lamps L.W., McCullough S., Hinson J.A. Tumor necrosis factor receptor 1 and hepatocyte regeneration in acetaminophen toxicity: a kinetic study of proliferating cell nuclear antigen and cytokine expression. Basic Clin Pharmacol Toxicol 2005, 97(1):8-14.
40. Chiu H., Gardener C.R., Dambach D.M., Brittingham J.A., Durham S.K., Laskin J.D., et al. Role of p55 tumor necrosis factor receptor 1 in acetaminophen-induced antioxidant defense. Am J Physiol-Gastrointest Liver Physiol 2003, 285(5):959-966.
41. Chiu H., Gardner C.R., Dambach D.M., Durham S.K., Brittingham J.A., Laskin J.D., et al. Role of tumor necrosis factor receptor 1 (p55) in hepatocyte proliferation during acetaminophen induced toxicity in mice. Toxicol Appl Pharmacol 2003, 193(2):218-227.
42. Yan S.L., Wu S.T., Yin M.C., Chen H.T., Chen H.C. Protective effects from carnosine and histidine on acetaminophen-induced liver injury. J Food Sci 2009, 74(8):259-265.
43. Yuan H.D., Jin G.Z., Piao G.C. Hepatoprotective effects of an active part from Artemisia sacrorum Ledeb. against acetaminophen-induced toxicity in mice. J Ethnopharmacol 2010, 127(2):528-533.
44. Rasool M.K., Sabina E.P., Ramya S.R., Preety P., Patel S., Mandal N., et al. Hepatoprotective and antioxidant effects of gallic acid in paracetamol-induced liver damage in mice. J Pharm Pharmacol 2010, 62(5):638-643.
45. Bourdi M., Eiras D.P., Holt M.P., Webster M.R., Reilly T.P., Wlech K.D., et al. Role of IL-6 in an IL-10 and IL-4 double knockout mouse model uniquely susceptible to acetaminophen-induced liver injury. Chem Res Toxicol 2007, 20(2):208-216.
46. Yee S.B., Bourdi M., Masson M.J., Pohl L.R. Hepatoprotective role of endogenous interleukin-13 in a murine model of acetaminophen-induced liver disease. Chem Res Toxicol 2007, 20(5):734-744.
47. Liu Z.X., Govindarajan S., Kaplowitz N. Innate immune system plays a critical role in determining the progression and severity of acetaminophen hepatotoxicity. Gastroenterology 2004, 127(6):1760-1774.
48. Zhang H., Cook J., Nickel J., Yu R., Stecker K., Myers K., et al. Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis. Nat Biotechnol 2000, 18:862-867.
49. Masson M.J., Carpenter L.D., Graf M.L., Pohl L.R. Pathogenic role of natural killer T and natural killer cells in acetaminophen-induced liver injury in mice is dependent on the presence of dimethyl sulfoxide. J Hepatol 2008, 48(3):889-897.
50. Ishida Y., Kondo T., Ohshima T., Fujiwara H., Iwakura Y., Mukaida N. A pivotal involvement of IFN-gamma in the pathogenesis of acetaminophen-induced acute liver injury. J Fed Am Societies Exp Biol 2002, 16(10):1227-1236.
51. Hogaboam C.M., Bone-Larson C.L., Steinhauser M.L., Matsukawa A., Gosling J., Boring L., et al. Exaggerated hepatic injury due to acetaminophen challenge in mice lacking C-C chemokine receptor 2. Am J Pathol 2000, 156(4):1245-1252.
52. Numata K., Kubo M., Watanabe H., Takagi K., Mizuta H., Okada S., et al. Over expression of suppressor of cytokine signaling-3 in T cells exacerbates acetaminophen-induced hepatotoxicity. J Immunol 2007, 178(6):3777-3785.
53. Takada H., Mawet E., Shiratori Y., Hikiba Y., Nakata R., Yoshida H., et al. Chemotactic factors released from hepatocytes exposed to acetaminophen. Dig Dis Sci J 1995, 40(8):1831-1836.
54. Horbach M., Gerber E., Kahl R. Influence of acetaminophen treatment and hydrogen peroxide treatment on the release of a CINC-related protein and TNF-alpha from rat hepatocyte cultures. J Toxicol 1997, 121(2):117-126.
55. Lawson J.A., Farhood A., Hopper R.D., Bajt M.L., Jaeschke H. The hepatic inflammatory response after acetaminophen overdose: role of neutrophils. Toxicol Sci 2000, 54(2):509-516.
56. Ishida Y., Kondo T., Kimura A., Tsuneyama K., Takayasu T., Mukaida N. Opposite roles of neutrophils and macrophages in the pathogenesis of acetaminophen-induced acute liver injury. Eur J Immunol 2006, 36(4):1028-1038.
57. Smith G.S., Nadig D.E., Kokoska E.R., Solomon H., Tiniakos D.G, Miller T.A. Role of neutrophils in hepatotoxicity induced by oral acetaminophen administration in rats. J Surg Res 1998, 80(2):252-258.
58. Liu Z.X., Han D., Gunawan B., Kaplowitz N. Neutrophil depletion protects against murine acetaminophen hepatotoxicity. J Hepatol 2006, 43(6):1220-1230.
59. Cover C., Liu J., Farhood A., Malle E., Waalkes M.P., Bajt M.L., et al. Pathophysiological role of the acute inflammatory response during acetaminophen hepatotoxicity. Toxicol Appl Pharmacol 2006, 216(1):98-107.
60. Williams C.D., Bajt M.L., Farhood A., Jaeschke H. Acetaminophen-induced hepatic neutrophil accumulation and inflammatory liver injury in CD18-deficient mice. Liver Int 2010, 30(9):1280-1292.
61. James L.P., McCullough S.S., Knight T.R., Jaeschke H., Hinson J.A. Acetaminophen toxicity in mice lacking NADPH oxidase activity: role of peroxynitrite formation and mitochondrial oxidant stress. Free Radic Res 2003, 37:1289-1297.
62. Jaeschke H., Liu J. Neutrophil depletion protects against murine acetaminophen hepatotoxicity: another perspective. J Hepatol 2007, 45(6):1588-1589.
63. Jaeschke H., Williams C.D., Ramachandran A., Bajt M.L. Acetaminophen hepatotoxicity and repair: the role of sterile inflammation and innate immunity. Liver Int 2011, 32(1):8-20.
64. Williams A.M., Langley P.G., Osei-Hwediah J., Wendon J.A., Hughes R.D. Hyaluronic acid and endothelial damage due to paracetamol-induced hepatotoxicity. Liver Int 2003, 23(2):110-115.
65. DeLeve L.D., Wang X., Kaplowitz N., Shulman H.M., Bart J.A., van der Hoek A. Sinusoidal endothelial cells as a target for acetaminophen toxicity. Direct action versus requirement for hepatocyte activation in different mouse strains. Biochem Pharmacol 1997, 53(9):1339-1345.
66. Ito Y., Bethna N.W., Abril E.R., McCuskey R.S. Early hepatic microvascular injury in response to acetaminophen toxicity. Microcirculation 2003, 10(5):391-400.
67. Salhanick S.D., Orlow D., Holt D.E., Pavlides S., Reenstra W., Buras J.A. Endothelially derived nitric oxide affects the severity of early acetaminophen-induced hepatic injury in mice. Acad Emerg Med 2006, 13(5):479-485.
68. Cavar I., Kelava T., Heinzel R., Culo F. The role of prostacyclin in modifying acute hepatotoxicity of acetaminophen in mice. Coll Anthropol 2009, 33(2):25-29.
69. Kato T., Ito Y., Hosono K., Suzuki T., Tamaki H., Minamino T., et al. Vascular growth factor receptor-1 signaling promotes liver repair through restoration of liver microvasculature after acetaminophen hepatotoxicity. Toxicol Sci 2011, 120(1):218-229.
70. Chaudhuri S., McCullough S.S., Hennings L., Letzig L., Simpson P.M., Hinson J.A., et al. Acetaminophen hepatotoxicity and HIF-1α induction in acetaminophen toxicity in mice occurs without hypoxia. Toxicol Appl Pharmacol 2011, 252(3):211-220.
71. Sparkenbaugh E.M., Saini Y., Greenwood K.K, LaPres J.J., Luyendyk J.P., Copple B.L., et al. The role of hypoxia-inducible factor-1α in acetaminophen hepatotoxicity. J Pharmacol Exp Ther 2011, 338(2):492-502.
72. Horton A.A., Wood J.M. Effects of inhibitors of phospholipase A2, cyclooxygenase and thromboxane synthetase on paracetamol hepatotoxicity in the rat. Eicosanoids 1989, 2(2):123-129.
73. Horton A.A., Wood J.M. Prevention of paracetamol-induced hepatotoxicity in the rat by the thromboxane receptor antagonist, Sulotroban (BM 13177). J Lipid Mediators Cell Signalling 1991, 4(2):245-247.
74. Reilly T.P., Brady J.N., Marchick M.R., Bourdi M., George J.W., Randovich M.F., et al. A protective role for cyclooxygenase-2 in drug-induced liver injury in mice. Chem Res Toxicol 2001, 14(12):1620-1628.
75. Cavar I., Kelava T., Vukojević K., Saraga-Babić M., Culo F. The role of prostaglandin E2 in acute acetaminophen hepatotoxicity in mice. Histol Histopathol 2010, 25(7):819-830.
76. Bernard P.H., Le Bail B., Carles J., Fawaz R., Balabaud C., Rosenbaum J., et al. Morphology of hepatic stellate cells in patients with fulminant or subfulminant hepatitis requiring liver transplantation. J Submicrosc Cytol Pathol 1996, 28(1):5-12.
77. Shen K., Chang W., Gao X., Wang H., Niu W., Song L., et al. Depletion of activated hepatic stellate cells correlates with severe liver damage and abnormal liver regeneration in acetaminophen-induced liver injury. Acta Biochim Biophys Sin (Shanghai) 2011, 43(4):307-315.
78. Connolly M.K., Ayo D., Malhorta A., Hackman M., Bedrosian A.S., Ibrahim J., et al. Dendritic cell depletion exacerbates acetaminophen hepatotoxicity. J Hepatol 2011, 54(3):959-968.
79. James L.P., Wells E., Beard R.H., Farrar H.C. Predictors of outcome after acetaminophen poisoning in children and adolescents. J Pediatr 2002, 140(5):522-526.
80. James L.P., Simpson P.M., Farrar H.C., Kearns G.L., Wasserman G.S., Blumer J.L., et al. Cytokines and toxicity in acetaminophen overdose. J Clin Pharmacol 2005, 45(10):1165-1171.
81. Payen C., Dachraoui A., Pulce C., Descotes J. Prothrombin time prolongation in paracetamol poisoning: a relevant marker of hepatic failure?. Hum Exp Toxicol 2003, 22(11):617-621.
82. Kerr R. New insights into haemostasis in liver failure. Blood Coagul Fibrinolysis 2003, 14(1):43-45.
83. Ganey P.E., Luyendyk J.P., Newport S.W., Eagle T.M., Maddox J.F., Mackman N., et al. Role of the coagulation system in acetaminophen-induced hepatotoxicity in mice. J Hepatol 2007, 46(4):1177-1186.
84. Markiewski M.M., DeAngelis R.A., Strey C.W., Foukas P.G., Gerard C., Gerard N., et al. The regulation of liver cell survival by complement. J Immunol 2009, 182(9):5412-5418.
85. Walport M.J. Complement. Second of two parts. N Engl J Med 2001, 344(15):1140-1144.
86. Ward P.A. The dark side of C5a in sepsis. Nat Rev Immunol 2004, 4(2):133-142.
87. Clapperton M., Rolando N., Sandoval L., Davies E., Williams R. Neutrophil superoxide and hydrogen peroxide production in patients with acute liver failure. Eur J Clin Invest 1997, 27(2):164-168.
88. Ellison R.T., Horsburgh C.R., Curd J. Complement levels in patients with hepatic dysfunction. Dig Dis Sci 1990, 35(2):231-235.
89. Singhal R., Ganey P.E., Roth R.A. The role of complement activation in acetaminophen-induced liver injury in mice. J Pharmacol Exp Ther 2012, 341(2):377-385.
90. Cousins M.J., Plummer J.L., Hall P.D. Risk factors for halothane hepatitis. Aust N Z J Surg 1989, 59(1):5-14.
91. You Q., Cheng L., Reilly T.P., Wegmann D., Ju C. Role of neutrophils in a mouse model of halothane-induced liver injury. J Hepatol 2006, 44(6):1421-1431.
92. Cheng L., You Q., Yin H., Holt M.P., Ju C. Involvement of natural killer T cells in halothane-induced liver injury in mice. Biochem Pharmacol 2010, 80(2):255-261.
93. Kobayashi E., Kobayashi M., Tsuneyama K., Fukami T., Nakajima M., Yokoi T. Halothane-induced liver injury is mediated by interleukin-17 in mice. Toxicol Sci 2009, 111(2):302-310.
94. Feng D., Wang Y., Xu Y., Luo Q., Lan B., Xu L. Interleukin 10 deficiency exacerbate halothane induced liver injury by increasing interleukin 8 expression and neutrophil infiltration. Biochem Pharmacol 2009, 77(2):277-284.
95. Dugan C.M., MacDonald A.E., Roth R.A., Ganey P.E. A mouse model of severe halothane hepatitis based on human risk factors. J Pharmacol Exp Ther 2010, 333(2):364-372.
96. Dugan C.M., Fullerton A.M., Roth R.A., Ganey P.E. Natural killer cells mediate severe liver injury in a murine model of halothane hepatitis. Toxicol Sci 2011, 120(2):507-518.
97. Masson M.J., Collins L.A., Carpenter L.D., Graf M.L., Ryan P.M., Bourdi M., et al. Pathological role of stressed-induced glucocorticoids in drug-induced liver injury in mice. Biochem Biophys Res Commun 2010, 397(3):453-458.
98. Toyoda Y., Miyashita T., Endo S., Tsuneyama K., Fukami T., Nakajima M., et al. Estradiol and progesterone modulate halothane-induced liver injury in mice. Toxicol Lett 2011, 204(1):17-24.
99. Sneed R.A., Grimes S.D., Schultze A.E., Brown A.P., Ganey P.E. Bacterial endotoxin enhances the hepatotoxicity of allyl alcohol. Toxicol Appl Pharmacol 1997, 144:77-87.
100. Barton C.C., Hill D.A., Yee S.B., Barton E.X., Ganey P.E., Roth R.A. Bacterial lipopolysaccharide exposure augments aflatoxin B1-induced liver injury. Toxicol Sci 2000, 55:444-452.
101. Yee S.B., Kinser S., Hill D.A, Barton C.C., Hotchkiss J.A., Harkema J.R., et al. Synergistic hepatotoxicity from coexposure to bacterial endotoxin and the pyrrolizidine alkaloid monocrotaline. Toxicol Appl Pharmacol 2000, 166:173-1850.
102. Rezende G., Roque-Afonso A.M., Samuel D., Gigou M., Nicand E., Ferre V., et al. Viral and clinical factors associated with the fulminant course of hepatitis A infection. J Hepatol 2003, 38(3):613-618.
103. Yaghi C., Honein K., Boujaoude J., Slim R., Moucari R., Sayegh R. Influence of acetaminophen at therapeutic doses on surrogate markers of severity of acute viral hepatitis. Gastroentérologie Clinique et Biologique 2006, 30(5):763-768.
104. Maddox J.F., Amuzie C.J., Li M., Newport S.W., Sparkenbaugh E., Cuff C.F., et al. Bacterial- and viral-induced inflammation increases sensitivity to acetaminophen hepatotoxicity. J Toxicol Environ Health Part A 2010, 73(1):58-73.
105. Gandhi A., Guo T., Ghose R. Role of c-Jun N-terminal kinase (JNK) in regulating tumor necrosis factor-alpha (TNF-alpha) mediated increase of acetaminophen (APAP) and chlorpromazine (CPZ) toxicity in murine hepatocytes. J Toxicol Sci 2010, 35(2):163-173.
106. Liu J., Sendelbach L.E., Parkinson A., Klaassen C.D. Endotoxin pretreatment protects against the hepatotoxicity of acetaminophen and carbon tetrachloride: role of cytochrome P450 suppression. J Toxicol 2000, 147(3):167-176.
107. Perino L.E., Warren G.H., Levine J.S. Cocaine-induced hepatotoxicity in humans. Gastroenterology 1987, 93:176-180.
108. Wanless I.R., Dore S., Gopinath N., Tan J., Cameron R., Heathcote E.J., et al. Histopathology of cocaine hepatotoxicity. Report of four patients. Gastroenterology 1990, 98:497-501.
109. Kanel G.C., Cassidy W., Shuster L., Reynolds T.B. Cocaine-induced liver cell injury: comparison of morphological features in man and in experimental models. J Hepatol 1990, 11:646-651.
110. Labib R., Turkall R., Abdel-Rahman M.S. Endotoxin potentiates cocaine-mediated hepatotoxicity by nitric oxide and reactive oxygen species. Int J Toxicol 2003, 22:305-316.
111. Labib R., Turkall R., Abdel-Rahman M.S. Endotoxin potentiates the hepatotoxicity of cocaine in male mice. J Toxicol Environ Health Part A 2002, 65:977-993.
112. Buchweitz J.P., Ganey P.E., Bursian S.J., Roth R.A. Underlying endotoxemia augments toxic responses to chlorpromazine: is there a relationship to drug idiosyncrasy?. J Pharmacol Exp Ther 2002, 300:460-467.
113. Luyendyk J.P., Maddox J.F., Cosma G.N., Ganey P.E., Cockerell G.L., Roth R.A. Ranitidine treatment during a modest inflammatory response precipitates idiosyncrasy-like liver injury in rats. J Pharmacol Exp Ther 2003, 307:9-16.
114. Waring J.F., Liguori M.J., Luyendyk J.P., Maddox J.F., Ganey P.E., Stachlewitz R.F., et al. Microarray analysis of LPS potentiation of trovafloxacin-induced liver injury in rats suggests a role for proinflammatory chemokines and neutrophils. J Pharmacol Exp Ther 2006, 316:1080-1087.
115. Deng X., Stachlewitz R.F., Liguori M.J., Blomme E.A., Waring J.F., Luyendyk J.P., et al. Modest inflammation enhances diclofenac hepatotoxicity in rats: role of neutrophils and bacterial translocation. J Pharmacol Exp Ther 2006, 319(3):1191-1199.
116. Shaw P.J., Hopfensperger M.J., Ganey P.E., Roth R.A. Lipopolysaccharide and trovafloxacin coexposure in mice causes idiosyncrasy-like liver injury dependent on tumor necrosis factor-alpha. Toxicol Sci 2007, 100(1):259-266.
117. Zou W., Devi S.S., Sparkenbaugh E., Younis H.S., Roth R.A., Ganey P.E. Hepatotoxic interaction of sulindac with lipopolysaccharide: role of the hemostatic system. Toxicol Sci 2009, 108:184-193.
118. Lu J., Jones A.D., Harkema J.R., Roth R.A., Ganey P.E. Amiodarone exposure during modest inflammation induces idiosyncrasy-like liver injury in rats: role of tumor necrosis factor-alpha. Toxicol Sci 2012, 125(1):126-133.
119. Roth R.A., Ganey P.E. Animal models of idiosyncratic drug-induced liver injury-current status. Crit Rev Toxicol 2011, 41(9):723-739.
120. Deng X., Luyendyk J.P., Ganey P.E., Roth R.A. Inflammatory stress and idiosyncratic hepatotoxicity: hints from animal models. Pharmacol Rev 2009, 61:262-282.
121. Shaw P., Ganey P.E., Roth R.A. Trovafloxacin enhances the inflammatory response to a gram-negative or a gram-positive bacterial stimulus, resulting in neutrophil-dependent liver injury in mice. J Pharmacol Exp Ther 2009, 330(1):72-78.
122. Cheng L., You Q., Yin H., Holt M., Franklin C., Ju C. Effect of polyI:C cotreatment on halothane-induced liver injury in mice. J Hepatol 2009, 49(1):215-226.
123. Tukov F.F., Luyendyk J.P., Ganey P.E., Roth R.A. The role of tumor necrosis factor alpha in lipopolysaccharide/ranitidine-induced inflammatory liver injury. Toxicol Sci 2007, 100(1):267-280.
124. Zou W., Beggs K.M., Sparkenbaugh E.M., Jones A.D., Younis H.S., Roth R.A., et al. Sulindac metabolism and synergy with tumor necrosis factorα in a drug-inflammation interaction model of idiosyncratic liver injury. J Pharmacol Exp Ther 2009, 331(1):114-121.
125. Shaw P.J., Beggs K.M., Sparkenbaugh E.M., Dugan C.M., Ganey P.E., Roth R.A. Trovafloxacin enhances TNF-induced inflammatory stress and cell death signaling and reduces TNF clearance in a murine model of idiosyncratic hepatotoxicity. Toxicol Sci 2009, 111(2):288-301.
126. Deng X., Lu J., Lehman-McKeeman L.D., Malle E., Crandall D.L., Ganey P.E., et al. p38 mitogen-activated protein kinase-dependent tumor necrosis factor-alpha-converting enzyme is important for liver injury in hepatotoxic interaction between lipopolysaccharide and ranitidine. J Pharmacol Exp Ther 2008, 326(1):144-152.
127. Shaw P.J., Ganey P.E., Roth R.A. Tumor necrosis factor alpha is a proximal mediator of synergistic hepatotoxicity from trovafloxacin/lipopolysaccharide coexposure. J Pharmacol Exp Ther 2009, 328(1):62-68.
128. Shaw P.J., Ditewig A.C., Waring J.F., Liguori M.J., Blomme E.A., Ganey P.E., et al. Coexposure of mice to trovafloxacin and lipopolysaccharide, a model of idiosyncratic hepatotoxicity, results in a unique gene expression profile and interferon gamma-dependent liver injury. Toxicol Sci 2009, 107(1):270-280.
129. Cosgrove B.D., King B.M., Hasan M.A., Alexopoulos L.G., Farazi P.A., Hendriks B.S., et al. Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity. Toxicol Appl Pharmacol 2009, 237(3):317-330.
130. Deng X., Luyendyk J.P., Zou W., Lu J., Malle E., Ganey P.E., et al. Neutrophil interaction with the hemostatic system contributes to liver injury in rats cotreated with lipopolysaccharide and ranitidine. J Pharmacol Exp Ther 2007, 322(2):852-861.
131. Zou W., Roth R.A., Younis H.S., Malle E., Ganey P.E. Neutrophil-cytokine interactions in a rat model of sulindac-induced idiosyncratic liver injury. J Toxicol 2011, 290(2-3):279-286.
132. Luyendyk J.P., Shaw P.J., Green C.D., Maddox J.F., Ganey P.E., Roth R.A. Coagulation-mediated hypoxia and neutrophil-dependent hepatic injury in rats given lipopolysaccharide and ranitidine. J Pharmacol Exp Ther 2005, 314:1023-1031.
133. Guigui B., Rosenbaum J., Préaux A.M., Martin N., Zafrani E.S., Dhumeaux D., et al. Toxicity of phorbol myristate acetate-stimulated polymorphonuclear neutrophils against rat hepatocytes. Demonstration and mechanism. Lab Invest 1988, 59(6):831-837.
134. Ho J.S., Buchweitz J.P., Roth R.A., Ganey P.E. Identification of factors from rat neutrophils responsible for cytotoxicity to isolated hepatocytes. J Leukoc Biol 1996, 59:716-724.
135. Shaw P.J., Fullerton A.M., Scott M.A., Ganey P.E., Roth R.A. The role of the hemostatic system in murine liver injury induced by coexposure to lipopolysaccharide and trovafloxacin, a drug with idiosyncratic liability. Toxicol Appl Pharmacol 2009, 236(3):293-300.
136. Luyendyk J.P., Maddox J.F., Green C.D., Ganey P.E., Roth R.A. Role of hepatic fibrin in idiosyncrasy-like liver injury from lipopolysaccharide-ranitidine coexposure in rats. J Hepatol 2004, 40:1342-1351.
137. Deng X., Liguori M.J., Sparkenbaugh E.M., Waring J.F., Blomme E.A., Ganey P.E., et al. Gene expression profiles in livers from diclofenac-treated rats reveal intestinal bacteria-dependent and -independent pathways associated with liver injury. J Pharmacol Exp Ther 2008, 327(3):634-644.
138. Zou W., Roth R.A., Younis H.S., Burgoon L.D., Ganey P.E. Oxidative stress is important in the pathogenesis of liver injury induced by sulindac and lipopolysaccharide cotreatment. Toxicology 2010, 272:32-38.